Daiichi Sankyo and Merck withdrew the I-DXd BLA in ES-SCLC after FDA discussions found phase 2 IDeate-Lung01 data insufficient for accelerated approval.
|Videos|August 19, 2011
Dr. Reckamp Describes the Use of Heat Shock Proteins
Author(s)Karen Reckamp, MD
Dr. Karen Reckamp from City of Hope Cancer Center Describes the Use of Heat Shock Proteins
Advertisement
Karen Reckamp, MD, MS, assistant professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California, describes early studies in lung cancer that examine heat shock proteins as single agents, specifically in ALK translocated patients and some EGFR wild type adenocarcinoma patients, which are less well defined. The proteins have shown success when used as a single agent when there is a resistance to crizotinib. Studies are currently underway that are investigating heat shock proteins in chemotherapy combination therapies.
Advertisement
Related to this article
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
5